一種A型和B型流感病毒檢測(cè)列表中包含了禽流感病毒H5N1分離株。該檢測(cè)方法已經(jīng)獲得了美國食品藥品管理局的許可。

這種檢測(cè)方法是由Binax公司研制開發(fā)的，該公司是Inverness醫(yī)學(xué)創(chuàng)新公司(Waltham, MA, USA)的分支機(jī)構(gòu)，該檢測(cè)方法叫做BinaxNOW流感A和B檢測(cè)。這種檢測(cè)是一種一步法快速檢測(cè)，能夠在15分鐘之內(nèi)準(zhǔn)確區(qū)別出流感病毒A和B型。即配即用型檢測(cè)能夠在流感爆發(fā)的時(shí)候有效地對(duì)患者作出診斷。

經(jīng)過確證的診斷方法能夠幫助醫(yī)務(wù)工作者選擇合適的治療方法，在疾病早期的時(shí)候采取干預(yù)措施。抗病毒治療能夠減少癥狀的嚴(yán)重程度，縮短疾病的病程，降低患者傳染給其它人的時(shí)間。因?yàn)殚_始病毒治療的時(shí)間窗只在出現(xiàn)癥狀的48小時(shí)之內(nèi)，能夠早期診斷的重要性是不言而喻的。

Inverness醫(yī)療創(chuàng)新公司是一家在全球范圍內(nèi)處于領(lǐng)先地位的體外診斷產(chǎn)品供應(yīng)商，該公司現(xiàn)在正在為其水平流體免疫檢測(cè)和其它用于各種診斷方法的技術(shù)開拓機(jī)會(huì)。

Influenza Panel Includes H5N1
 
A test for influenza A and B now includes avian influenza H5N1 isolates in its list of influenza strains. The test has been cleared by the U.S. Food and Drug Administration (FDA).

The test was developed by Binax Inc., a subsidiary of Inverness Medical Innovations (Waltham, MA, USA), and is called the BinaxNOW influenza A and B test. The test is a one-step, rapid test that is able to clearly differentiate between influenza A and influenza B in 15 minutes. Use of the easy-to-read test can help diagnose patients efficiently in the event of an outbreak of influenza.

A confirmed diagnosis helps healthcare workers to select appropriate treatments and to begin administration early in the process. Antivirals can reduce the severity of symptoms, shorten the duration of illness, and reduce the time during which patients can be infectious to others. Since the window of opportunity to begin antiviral treatment is only 48 hours from the onset of symptoms, these capabilities are very important.

Inverness Medical Innovations is a leading global provider of in vitro diagnostic products that is now exploring new opportunities for its lateral flow immunoassay and other proprietary technologies for various professional diagnostic applications.